|
1
|
Siegel R, DeSantis C, Virgo K, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Broglio KR and Berry DA: Detecting an
overall survival benefit that is derived from progression-free
survival. J Natl Cancer Inst. 101:1642–1649. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soria JC, Massard C and Le Chevalier T:
Should progression-free survival be the primary measure of efficacy
for advanced NSCLC therapy? Ann Oncol. 21:2324–2332. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reck M, von Pawel J, Zatloukal P, et al:
Phase III trial of cisplatin plus gemcitabine with either placebo
or bevacizumab as first-line therapy for nonsquamous non-small-cell
lung cancer: AVAil. J Clin Oncol. 27:1227–1234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Saad ED, Katz A and Buyse M: Overall
survival and post-progression survival in advanced breast cancer: a
review of recent randomized clinical trials. J Clin Oncol.
28:1958–1962. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sundar S, Wu J, Hillaby K, Yap J and
Lilford R: A systematic review evaluating the relationship between
progression free survival and post progression survival in advanced
ovarian cancer. Gynecol Oncol. 125:493–499. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petrelli F and Barni S: Correlation of
progression-free and post-progression survival with overall
survival in advanced colorectal cancer. Ann Oncol. 24:186–192.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hotta K, Kiura K, Fujiwara Y, et al: Role
of survival post-progression in phase III trials of systemic
chemotherapy in advanced non-small-cell lung cancer: a systematic
review. PLoS One. 6:e266462011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hayashi H, Okamoto I, Morita S, Taguri M
and Nakagawa K: Postprogression survival for first-line
chemotherapy of patients with advanced non-small-cell lung cancer.
Ann Oncol. 23:1537–1541. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Imai H, Takahashi T, Mori K, et al:
Individual-level data on the relationships of progression-free
survival, post-progression survival, and tumor response with
overall survival in patients with advanced non-squamous non-small
cell lung cancer. Neoplasma. 61:233–240. 2014. View Article : Google Scholar
|
|
11
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitsudomi T, Morita S, Yatabe Y, et al;
West Japan Oncology Group. Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): an
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar
|
|
13
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Inoue A, Kobayashi K, Maemondo M, et al:
Updated overall survival results from a randomized phase III trial
comparing gefitinib with carboplatin-paclitaxel for chemo-naive
non-small cell lung cancer with sensitive EGFR gene mutations
(NEJ002). Ann Oncol. 24:54–59. 2013. View Article : Google Scholar
|
|
15
|
Nagai Y, Miyazawa H, Huqun, et al: Genetic
heterogeneity of the epidermal growth factor receptor in non-small
cell lung cancer cell lines revealed by a rapid and sensitive
detection system, the peptide nucleic acid-locked nucleic acid PCR
clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar
|
|
16
|
Yatabe Y, Hida T, Horio Y, Kosaka T,
Takahashi T and Mitsudomi T: A rapid, sensitive assay to detect
EGFR mutation in small biopsy specimens from lung cancer. J Mol
Diagn. 8:335–341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
18
|
Johnson KR, Ringland C, Stokes BJ, et al:
Response rate or time to progression as predictors of survival in
trials of metastatic colorectal cancer or non-small-cell lung
cancer: a meta-analysis. Lancet Oncol. 7:741–746. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hotta K, Fujiwara Y, Matsuo K, et al: Time
to progression as a surrogate marker for overall survival in
patients with advanced non-small cell lung cancer. J Thorac Oncol.
4:311–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weir CJ and Walley RJ: Statistical
evaluation of biomarkers as surrogate endpoints: a literature
review. Stat Med. 25:183–203. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fleischer F, Gaschler-Markefski B and
Bluhmki E: A statistical model for the dependence between
progression-free survival and overall survival. Stat Med.
28:2669–2686. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Foster NR, Qi Y, Shi Q, et al: Tumor
response and progression-free survival as potential surrogate
endpoints for overall survival in extensive stage small-cell lung
cancer: findings on the basis of North Central Cancer Treatment
Group trials. Cancer. 117:1262–1271. 2011. View Article : Google Scholar
|
|
23
|
Berghmans T, Pasleau F, Paesmans M, et al:
ELCWP: Surrogate markers predicting overall survival for lung
cancer: ELCWP recommendations. Eur Respir J. 39:9–28. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tsujino K, Kawaguchi T, Kubo A, et al:
Response rate is associated with prolonged survival in patients
with advanced non-small cell lung cancer treated with gefitinib or
erlotinib. J Thorac Oncol. 4:994–1001. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li X, Liu S, Gu H and Wang D: Surrogate
end points for survival in the target treatment of advanced
non-small-cell lung cancer with gefitinib or erlotinib. J Cancer
Res Clin Oncol. 138:1963–1969. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tomizawa Y, Fujita Y, Tamura A, et al:
Effect of gefitinib re-challenge to initial gefitinib responder
with non-small cell lung cancer followed by chemotherapy. Lung
Cancer. 68:269–272. 2010. View Article : Google Scholar : PubMed/NCBI
|
